Hyderabad-based, Aurobindo Pharma has received the approval for its chewable and dispersible Lamotrigine tablets from the US Food & Drug Administration (USFDA).
With this latest approval, the pharma major has a total of 107 approvals from USFDA in its kitty.
Lamotrigine tablets 5mg and 25mg is generic equivalent to Lamictal CD tablets 5 mg and 25 mg of GlaxoSmithKline, the compay said in a statement today. It falls under the central nervous system (CNS) segment and is indicated as adjunctive therapy for partial seizures and generalised seizures of Lennox-Gastaut syndrome in patients aged 2 years and older.
On the Bombay Stock Exchange, the company's stocks were trading at Rs 828, up 2.44 per cent at IST 1140.
